Recent studies have shown EZH2 to be an oncogene in BRAF-driven melanoma [63], and combination therapy of the BRAF inhibitor vemurafinib with JQ1 [64] or DNA methyltransferase inhibitor decitabine [65] displayed efficacy in pre-clinical melanoma models. The gene discussed is BRAF; the disease is melanoma.